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A unit risk factor (URF) was developed for hexavalent chromium (CrVI). The URF is based on excess lung
cancer mortality in two key epidemiological studies of chromate production workers. The Crump et al.
(2003) study concerns the Painesville, OH worker cohort, while Gibb et al. (2000) regards the Baltimore,
MD cohort. A supporting assessment was also performed for a cohort from four low-dose chromate plants
(Leverkusen and Uerdingen, Germany, Corpus Christi, TX, Castle Hayne, NC). For the Crump et al. (2003)
study, grouped observed and expected number of lung cancer mortalities along with cumulative CrVI
exposures were used to obtain the maximum likelihood estimate and asymptotic variance of the slope
(b) for the linear multiplicative relative risk model using Poisson regression modeling. For the Gibb
et al. (2000) study, Cox proportional hazards modeling was performed with optimal exposure lag and
adjusting for the effect of covariates (e.g., smoking) to estimate b values. Life-table analyses were used
to develop URFs for each of the two key studies, as well as for supporting and related studies. The two
key study URFs were combined using weighting factors relevant to conﬁdence to derive the ﬁnal URF
for CrVI of 2.3E-03 per lg CrVI/m3.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Human and animal studies have shown that hexavalent chro-
mium (CrVI) has the ability to induce carcinogenicity. That is, high
long-term, occupational and experimental animal inhalation expo-
sure to CrVI concentrations several orders of magnitude higher
than environmental levels has the ability to induce lung cancer
(De Flora, 2000; ATSDR, 2012). The causal relationship between
the inhalation of Cr and lung cancer was suspected as early as
the late 19th century (discussed in Jones, 1990; McCarroll et al.,
2009). Particulate forms of CrVI, relatively water insoluble com-
pounds more speciﬁcally, appear to be more potent lung carcino-
gens, with prolonged extracellular dissolution of the CrVI
compound critical to potency (O’Brien et al., 2003; Holmes et al.,
2008; ATSDR, 2012; Nickens et al., 2010). ATSDR (2012) indicates
that epidemiology studies (e.g., chromate worker studies) show a
strong association between occupational CrVI exposure and lung
cancer, which has been used as the cancer endpoint and corrobo-
rated in numerous studies.
The USEPA considers CrVI as a known human carcinogen by the
inhalation route of exposure based on occupational epidemiologicstudies of chromium-exposed workers, dose–response relation-
ships for CrVI exposure and lung cancer, and positive carcinogenic
animal data for CrVI (USEPA, 1998). The International Agency for
Research on Cancer (IARC Monograph Volume 100C) has also
determined that CrVI compounds are carcinogenic to humans
(IARC, 2012). Additionally, the National Toxicology Program
(NTP) 12th Report on Carcinogens classiﬁes CrVI compounds as
known to be human carcinogens (NTP, 2011). Consistent with
these weight of evidence classiﬁcations, the Texas Commission
on Environmental Quality (TCEQ) considers CrVI and CrVI com-
pounds as a group to be carcinogenic to humans via inhalation.
The United States Environmental Protection Agency (USEPA)
completed health assessments of chromium and CrVI in 1984
and 1998, respectively (USEPA, 1984, 1998). However, there are
studies more recent than those available for evaluation at that
time, including more recent studies for dose–response assessment
of lung cancer mortality in chromate workers (e.g., Gibb et al.
(2000) and Crump et al. (2003)). Additionally, CrVI has been de-
tected in ambient air in Texas. Thus, it is important for the TCEQ
to conduct an inhalation carcinogenic assessment of CrVI based
on the latest scientiﬁc data and analyses in order to develop a unit
risk factor (URF) to help ensure the protection of public health.
A URF for CrVI has been developed based on new dose–response
analyses of lung cancer mortality data in the key epidemiological
studies of Crump et al. (2003) and Gibb et al. (2000). The Crump
et al. (2003) study, which is an update of the Mancuso (1975)
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USEPA health assessments of chromium and CrVI (USEPA, 1984,
1998). Neither were various supporting or related studies (e.g., Ap-
plied Epidemiology (2002), Luippold et al. (2003), Park et al.
(2004)). The cancer assessment section of TCEQ’s Hexavalent Chro-
mium and Compounds Development Support Document Draft (DSD,
referenced as TCEQ (2013)) underwent an external scientiﬁc peer
review organized by Toxicology Excellence for Risk Assessment
(TERA, 2013) and a public comment period. That document is the
source of the assessment presented herein. None of the comments
affected the ﬁnal inhalation URF value. The purpose of this paper is
to present the procedures used in the carcinogenic assessment of
CrVI, the derived URFs, and the ﬁnal weighted URF. The ﬁnal URF
will be used to calculate the associated air concentrations at vari-
ous de minimis extra lung cancer risk levels.2. Materials and methods
The TCEQ (2012) guidelines for carcinogenic assessment em-
ploy the four-step risk assessment process formalized by the NRC
(1983, 1994) and the procedures recommended in the most recent
USEPA cancer guidelines (USEPA, 2005a,b) and scientiﬁc literature.
For chronic adverse effects determined or assumed to be associated
with linear dose–response relationships in the low-dose region,
which is the case for CrVI-induced lung cancer, the TCEQ adopts
or derives URFs. That is, for adverse effects associated with or as-
sumed to have a linear dose–response at low doses (typically can-
cer), it is assumed that an effects threshold does not exist. In such
cases, a linear extrapolation is performed to estimate excess life-
time risk at lower doses, for example, through use of the calcula-
tion of a point of departure using BEIR IV methodology (NRC,
1988) if data have been ﬁt to a dose–response model. The slope
of the line from zero excess risk at zero exposure to this point of
departure is the inhalation URF, which may be described as the ex-
cess risk estimated to result from continuous lifetime exposure to
an agent on a per lg/m3 in air basis (i.e., excess risk per lg/m3
assuming continuous lifetime exposure).
Human studies are preferred for URF derivation per the TCEQ
(2012) guidelines, and in addition to reviewing the epidemiological
studies previously considered and/or utilized by other agencies
(e.g., USEPA, OSHA, NIOSH) for URF development, the TCEQ con-
ducted a scientiﬁc literature search (through February 2013) for
more recent CrVI inhalation epidemiological studies with adequate
data for URF derivation. As with all chemicals for which TCEQ is
developing toxicity factors, external interested parties had ample
opportunity to submit relevant information (e.g., published,
unpublished studies). See Section 3.3.2 of TCEQ (2012) for addi-
tional information on the procedures and sources used to identify
essential data such as that from the key studies discussed herein.
The URF is based on excess lung cancer mortality in two key
epidemiological studies of chromate production workers which
are adequate to deﬁne dose–response relationships. The Crump
et al. (2003) study concerns the Painesville, OH worker cohort of
482 workers, while Gibb et al. (2000) regards the Baltimore, MD
cohort of 2357 workers. These cohorts have extensive follow-up
and their respective studies provide standard mortality ratio
(SMR) analyses for lung cancer mortality by cumulative CrVI expo-
sure level (individual worker data are also available for Gibb et al.
(2000)). Additional details on these key epidemiological studies are
provided below.3. Carcinogenic assessment
The following sections discuss key steps in the carcinogenic
assessment of CrVI and development of URFs. Consistent withFigs. 1 and 2a of TCEQ (2012), the key steps are generally as
follows:
 Conduct literature review and solicit information from inter-
ested parties.
 Perform carcinogenic weight of evidence and mode of action
analyses (linear low-dose extrapolation is the default for a
mutagenic or unknown mode of action).
 Identify key studies with sufﬁcient information to conduct
dose–response analyses (human study data are preferred and
available for CrVI).
 Conduct dose–response modeling with the best methods avail-
able to derive slope parameter (b) estimates (linear multiplica-
tive relative risk model using Poisson regression modeling, Cox
proportional hazards modeling).
 Develop URFs using the best available method (life-table analy-
ses were used in this case).
 Combine key study preferred URFs using weighting factors rel-
evant to conﬁdence to derive the ﬁnal URF (inverse variance of
the b estimates was used).
The ﬁrst two steps shown above (i.e., literature search, carcino-
genic weight of evidence and mode of action analyses) are inher-
ently part of the process but need not be addressed in detail here
since the focus of this paper is on documentation of the dose–re-
sponse analyses and methods used in the URF derivation process.
The ﬁrst step was brieﬂy discussed generally in the previous sec-
tion. Additionally, carcinogenic weight of evidence analyses have
already been conducted by many agencies (e.g., USEPA, ATSDR,
IARC, NTP) and agree that CrVI is carcinogenic to humans via inha-
lation, and a mode of action analysis would not result in a depar-
ture from the linear, low-dose extrapolation approach employed
in this study. Consequently, the following sections focus on the last
four steps shown above.
3.1. Key studies
Human epidemiological studies are available and preferable
over animal studies for the development of a URF. Not all epidemi-
ological studies are adequate to deﬁne dose–response relation-
ships, although numerous studies have investigated the
association of CrVI exposure and lung cancer. The Painesville, OH
(e.g., Crump et al. (2003)) and Baltimore, MD (e.g., Gibb et al.
(2000)) chromate production worker cohorts have been used for
quantitative risk assessment of lung cancer previously (e.g., OSHA
(2006)). These cohorts are relatively large, have extensive follow-
up, and documentation of historical CrVI exposure levels. Summary
information for these key epidemiological studies, taken from ATS-
DR (2012), is presented below. Additionally, a cohort of workers
from four low-dose chromate plants (Leverkusen and Uerdingen,
Germany, Corpus Christi, TX, Castle Hayne, NC) is the subject of
various studies (e.g., Applied Epidemiology (2002), Birk et al.
(2006)) and has been identiﬁed for a supporting quantitative
dose–response assessment. Summary information for this support-
ing epidemiological study is also provided below.
3.1.1. Key cohorts: Painesville, OH and Baltimore, MD
3.1.1.1. Painesville, OH. Several studies have found increased lung
cancer mortality (standard mortality ratios or SMRs) among work-
ers at the chromate production plant in Painesville, OH (e.g., Man-
cuso (1997)). More recent studies of this cohort (Crump et al.
(2003), Luippold et al. (2003)) have reconstructed individual expo-
sure histories to CrVI based on species-speciﬁc air monitoring data,
and have attempted to quantify the potential lung cancer risk con-
tribution of smoking. These studies included 482 workers em-
ployed for at least 1 year from 1940 to 1972 and followed
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Fig. 1. Percentage of Baltimore chromate workers with lung cancer mortality by work duration (Tipton, 2007).
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Fig. 2. Lung cancer incidence versus mortality (SEER, 2008).
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was signiﬁcantly associated with increased lung cancer risk. Addi-
tionally, study results indicated that smoking did not have a
substantial effect on CrVI lung cancer risk results (i.e., smoking
and CrVI appeared to contribute independently to cancer risk)
since risk estimates were not appreciably sensitive to smoking des-
ignation (for the 41% of the cohort that could be classiﬁed) (ATSDR,
2012).
Crump et al. (2003) provide one of the best summary SMR data-
sets for dose–response assessment due to a relatively high number
of exposure groups (10) evaluated for excess lung cancer risk. The
cumulative exposure and SMR data which will be used to calculate
the slope parameter (b) estimates based on Crump et al. (2003) are
given in Table 1 below.
Luippold et al. (2003) also evaluated the Painesville cohort, but
only used 5 exposure groups. A trend test showed a strong rela-
tionship between lung cancer mortality (SMRs) and cumulative
CrVI exposure. However, because exposure was not lagged and
fewer cumulative exposure groups are provided for dose–response
modeling, Crump et al. (2003) is considered to provide the best
dose–response dataset for the Painesville, OH cohort and is used
for the assessment of this cohort. Modeled data and results for
Luippold et al. (2003) may be found in TCEQ (2013).3.1.1.2. Baltimore, MD. Gibb et al. (2000) evaluated lung cancer
mortality in a cohort of 2357 male chromate production workers
in Baltimore, MD hired during 1950–1974, with mortality followed
through 1992. Several earlier studies had found signiﬁcantly in-
creased lung cancer mortality (SMRs) among workers at the plant
(e.g., Hayes et al. (1979)). Cumulative exposures to CrVI or CrIII
(mg/m3-yr) were reconstructed for each worker from historical
air monitoring data and job title records (note that the cumulative
CrO3 exposure levels reported by Gibb et al. (2000) were converted
to their CrVI equivalents based on molecular weight for this assess-
ment). As a group, the lung cancer SMR was 1.80 (95% CI of 1.49–
2.14). Other studies have also reanalyzed the data (e.g., Park et al.
(2004), Environ (2003), Park and Stayner (2006)).
The TCEQ does, however, have concerns about the Baltimore co-
hort. Most notably, concerns regard the short exposure duration
for many workers in this cohort. Forty-two percent of the Balti-
more cohort worked in chromium production less than 3 months,
with a median of around 4.5 months. Approximately 60% of the
person-years at risk were from workers employed less than
6 months, with only about 15% of the cohort working forP5 years.
By contrast, the median tenure for the Painesville workers was
about 16 times longer at 6 years, with 17% working more than
20 years (as opposed to 15% workingP5 years in the Baltimore co-
Table 1
Cumulative exposure and lung cancer standardized mortality ratio (SMR) data from Table IV of Crump et al. (2003).
Cumulative exposure range (mg CrVI/m3-yr)a Average cumulative exposure (mg CrVI/m3-yr)a Observed (O) Expected (E)b Lung cancer SMR (O/E)
0–0.06 0.00976 0 2.09 0
0.06–0.18 0.115 3 2.19 1.4
0.18–0.30 0.233 3 2.19 1.4
0.30–0.46 0.386 5 2.13 2.3
0.46–0.67 0.563 0 2.20 0
0.67–1.00 0.817 4 2.22 1.8
1.00–1.63 1.27 12 2.23 5.4
1.63–2.60 2.09 3 2.18 1.4
2.60–4.45 3.37 10 2.18 4.6
4.45–29.0 7.55 11 2.12 5.2
a Exposure lagged 5 yrs.
b Based on Ohio rates.
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these short-term workers died of lung cancer. For example, 43%
and 54% of lung cancer deaths occurred in those who worked for
less than 6 and 12 months, respectively. Because short-term work-
ers (e.g., <1 year) have been found more likely to lead an unhealthy
lifestyle (e.g., abuse alcohol) and have a chronic disease such as
cancer (Kolstad and Olsen, 1999), have increased mortality (Kols-
tad and Olsen, 1999; Steenland et al., 1996), and have increased
SMRs for respiratory and other cancers (Bonfetta et al., 1997), their
risk factors may differ from long-term workers and the general
population (e.g., perhaps biasing low-dose risk high when the gen-
eral population is the referent as in Gibb et al. (2000)). Addition-
ally, the exposure scenario the Baltimore cohort experienced is
most dissimilar to the lifetime, environmental exposure scenario
of interest and therefore least relevant and likely most uncertain
for occupational-to-lifetime, low level environmental extrapola-
tion. Consequently, the TCEQ and others (e.g., Kolstad and Olsen
(1999), Steenland et al. (1996)) consider inclusion of short-term
workers as potentially problematic for assessing risk from long-
term, low-dose exposure (although this was the reason these
workers were included in Gibb et al.). Thus, the analysis for the Bal-
timore cohort will include a subset of workers exposed at least
1 year, which was also the worker inclusion criterion for the other
cohorts evaluated herein. Other concerns about the Baltimore co-
hort, such as not controlling for smoking, have been discussed by
other authors (e.g., Exponent (2002a,b)).
Because of increased concerns about this cohort, Cox propor-
tional hazards modeling will be performed using the Gibb et al. co-
hort individual data including smoking as a covariate. The Cox
model is superior to Poisson regression modeling in that Cox mod-
eling uses individual exposure estimates and optimally controls for
the effect of age. However, for comparison to less reﬁned modeling,
modeled data and results for Gibb et al. (2000), Park et al. (2004)
and , and Environ (2003) using maximum likelihood estimation
procedures and Poisson regression modeling may be found in TCEQ
(2013).
3.1.2. Low-dose supporting cohorts: Leverkusen and Uerdingen,
Germany, Corpus Christi, TX, and Castle Hayne, NC
In addition to using the Painesville (Crump et al., 2003) and Bal-
timore (Gibb et al., 2000) cohorts for URF calculations, supporting
dose–response data will be utilized from 1518 workers employed
for at least 1 year who were exposed to low CrVI levels resulting
from improved industrial hygiene practices and conversion to a
low- or no-lime chromate production process. These low-exposed
workers were followed through 1998 and are from four chromate
production plants: Leverkusen and Uerdingen, Germany (total of
901 workers at these two plants), Corpus Christi, TX (187 workers),
and Castle Hayne, NC (430 workers). Birk et al. (2006) evaluated
only the two German plants. However, Applied Epidemiology
(2002) evaluated all four plants and will be the primary focus forthis supporting assessment. The range of exposure durations for
individual workers in the 4-plant study was 1.0–40.7 years, with
mean exposure durations for the four plants ranging from 7.8 to
12.4 years and an overall mean exposure duration for the 4-plant
study of 9.8 years.
For these low-exposed workers, cumulative exposure was re-
ported as urinary chromium (lg Cr/L urine-yr). Therefore, cumula-
tive urinary chromium was converted by the TCEQ to the
cumulative air exposure equivalent dose metric (mg CrVI/m3-yr)
using the following biological exposure index (BEI)-type conver-
sion established based on the relationship between urinary chro-
mium and CrVI air concentration (Forschungsgemeinschaft, 1994):mg CrVI=m3  yr ¼ lg Cr=L urine yr=½0:77 lg=L in urine
per 1 lg CrVI=m3 in the air 1000 lg=mg
This BEI conversion is applicable to workers at the two German
plants in Birk et al. (2006) and Applied Epidemiology (2002), and
was used in Applied Epidemiology (2002) to covert CrVI air con-
centrations for the workers at the two American plants to urinary
concentrations. Thus, for the American workers in Applied Epide-
miology (2002), the reverse procedure simply converts cumulative
urinary chromium back to the cumulative air exposure dose metric
(mg CrVI/m3-yr) for this assessment. Both Applied Epidemiology
(2002) and Birk et al. (2006) found excess lung cancer risk in the
highest unlagged exposure group (P200 lg Cr/L-yr) based on
SMR analyses. Logistic regression analyses found increased odds
ratios for the intermediate and/or high exposure groups after
adjusting for smoking (Applied Epidemiology, 2002; Birk et al.,
2006), and that adjusting for smoking did not materially change
the relationship between CrVI exposure and lung cancer.
Although these supporting studies have some limitations (e.g.,
shorter follow-up time), the lower air concentration exposures
(long-term plantwide geometric means generally <4 lg CrVI/m3
for all four plants) are considered advantageous for assessing
low-dose risk. The midpoint of the cumulative exposure range
for the highest exposure group for these lower-exposed workers
(509.74 lg CrVI/m3-yr), for example, is approximately 33 times
lower than that in the highest exposure group for the Painesville
cohort (16,725 lg CrVI/m3-yr) and would fall into the lower half
of the cumulative exposure groups evaluated for that cohort
(Crump et al., 2003). The 4-plant study (Applied Epidemiology,
2002) has three times as many person-years (24,589) at these low-
er exposures (e.g., 60.67 mg CrVI/m3-yr) as the Painesville cohort
study (8076). Basing supporting risk estimates (i.e., URFs) on
dose–response data from lower-exposed workers is considered
more relevant for assessing risk associated with the lower environ-
mental air concentrations to which the general public may be ex-
posed (i.e., helps ensure generalizability to potential general
public exposures). It also reduces the magnitude of downward
extrapolation and the uncertainty associated with low-dose
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ronmentally-relevant CrVI air concentrations (e.g., at a 1 in 100,000
excess risk level). Additionally, the US low-exposed workers pro-
vide diversity as less than 1% of the workers in the Painesville co-
hort were female, whereas 16% were women at these low-
exposure US plants (also, 25% of the plant workers were African–
American or Hispanic). Lastly, as potential CrVI emission sources,
these types of chromate production plants are representative of
current plants in the US.
Despite some advantageous attributes, use of the Applied Epi-
demiology (2002) 4-plant study is being limited to that of a sup-
porting study due to the relatively short, mean follow-up time of
17.2 years compared to the latency for CrVI-induced lung cancer
deaths (e.g., 86% of lung cancer deaths occurred P20 years after
ﬁrst exposure in the Painesville cohort, Luippold et al. (2003)).
Additionally, only 10.3% of the cohort was deceased. These factors
may limit the power of this study to detect increases in risk due to
low cumulative exposure compared to the Baltimore cohort
(30.0 years follow-up, 36% deceased) and Painesville cohort
(30.4 years follow-up, 63% deceased) (Gibb et al., 2000; OSHA,
2006; Luippold et al., 2003; Crump et al., 2003). The cumulative
exposure and SMR data which will be used to calculate the param-
eter (b) estimates based on Applied Epidemiology (2002) are given
in Table 2 below. Modeled data and results for the smaller 2-plant,
low-dose study of Birk et al. (2006) may be found in TCEQ (2013).3.2. Dose metric
The key chromate production plant epidemiological studies dis-
cussed above and used for URF development all evaluated lung
cancer mortality by cumulative exposure level (e.g., mg CrVI/m3-
yr). Thus, the dose metric used for the dose–response assessment
is cumulative CrVI exposure not only because it is the only com-
mon measure available from the key studies, but also because
cumulative exposure is the dose metric commonly used for
dose–response modeling based on epidemiological studies. Appli-
cation of the URF (derived using cumulative exposure to CrVI as
the dose metric) to all CrVI compounds inherently treats all CrVI
compounds as toxicologically equivalent based on CrVI content,
consistent with the TCEQ considering CrVI compounds as a group
to be ‘‘Carcinogenic to Humans.’’3.3. Dose–response assessment: slope parameter (b) estimates
3.3.1. Poisson regression modeling – Crump et al. (2003) and Applied
Epidemiology (2002)
For lung cancer mortality in the studies evaluated, Poisson
regression modeling was used to calculate the maximum likeli-
hood estimate (MLE) of the slope parameter b. Maximum likeli-
hood estimation with Poisson regression is preferred when the
number of responses (i.e., observed and expected cases) is known
(Section 8.3.3.2.1.1 of USEPA (1986), Crump and Allen (1985)), as
in this case. The multiplicative relative risk model used to calculateTable 2
Lung cancer standardized mortality ratio (SMR) from Table 15 of Applied Epidemiology (2
Cumulative exposure in urine
(lg Cr/L-yr)
Midpoint converted to air cumulative exposure
equivalentb (lg CrVI/m3-yr)
0–39.9 25.97
40–99.9 90.91
100–199.9 194.81
200–585a 509.74
a Upper end of exposure range based on Figure 23 in Applied Epidemiology (2002).
b Midpoint of cumulative urinary exposure converted to the air CrVI equivalent using
c Number of expected (E) calculated as number of observed (O)/SMR.the b value included a term (a) to account for differences in lung
cancer mortality background rates between the study population
and the reference population used to determine the number of ex-
pected lung cancer mortalities. The use of this term may account
for potential issues such as the healthy worker effect and any dif-
ferences between internally- and externally-derived background
rates. Incorporation of the a term into the relative risk model equa-
tion from USEPA (1986, pp. 8–201) yields:
EðOjÞ ¼ a Eoj  ð1þ b djÞ
where:
E(Oj) = expected number of lung cancer mortality cases for
exposure group j
a = accounts for differences in lung cancer mortality back-
ground rates between the study population and the reference
population
Eoj = expected number of background lung cancer mortality
cases for exposure group j
b = multiplicative factor by which background risk increases
with cumulative exposure
dj = cumulative exposure for exposure group j
The linear multiplicative relative risk model, as opposed to an
additive risk model, was used to calculate b estimates. The multi-
plicative relative risk model is preferred over the additive risk
model for lung cancer because of more plausible assumptions con-
cerning the increase in risk with age. For lung cancer, risk increases
rapidly with age, which is better captured by the multiplicative rel-
ative risk model where risk increases over background rates multi-
plicatively. By contrast, the additive risk model assumes that
cumulative exposure causes the same absolute increase in risk
regardless of the age at which the risk is calculated, which is less
plausible relative to actual observed age-related increases in lung
cancer incidence and mortality.
For Crump et al. (2003) and Applied Epidemiology (2002), the
mean or midpoint of each cumulative exposure group in units of
lg CrVI/m3-yr was used to estimate b values. Table 3 presents b
estimates for Crump et al. (2003) and Applied Epidemiology
(2002) evaluated in units of increase of relative risk per lg CrVI/
m3-yr.
Consistent with USEPA (2005a) and TCEQ (2012) guidelines, the
standard error (SE), 95% lower conﬁdence limit on the b (95% LCL
b), and 95% upper conﬁdence limit on the b (95% UCL b) were also
calculated and are presented. As the 95% LCL b values for the 4-
plant, low-dose worker study (Applied Epidemiology, 2002) were
negative, suggesting zero excess risk, these 95% LCL b values are
not carried further in the dose–response assessment.3.3.2. Cox proportional hazards modeling – Gibb et al. (2000)
As previously indicated, Cox proportional hazards modeling
was performed for a more extensive analysis of the Gibb et al.
(2000) data for the Baltimore, MD cohort to offset some002).
No lag SMR
(O/E)c
10-Yr lagged exposure
SMR (O/E)c
20-Yr lagged exposure
SMR (O/E)c
1.35 (4/2.96) 1.34 (9/6.72) 1.31 (17/12.98)
0.95 (4/4.21) 0.78 (3/3.85) 1.01 (2/1.98)
0.94 (5/5.32) 1.31 (5/3.82) 1.10 (2/1.82)
2.09 (12/5.74) 2.05 (8/3.90) 2.74 (4/1.46)
the urine-to-air conversion factor of 1 lg CrVI/m3/0.77 lg/L.
Table 3
b values and standard error (SE) based on lung cancer mortality.
Study Lag a SE b (95% LCL)a,b b (MLE)a b (95% UCL)a,c
Crump et al. (2003) Painesville, OH 5-yr 1.15 3.22E-04 1.05E-04 6.34E-04 1.16E-03
Applied Epidemiology (2002) Leverkusen and Uerdingen, Germany, Corpus Christi,
TX and Castle Hayne, NC
None 0.88 2.58E-03 1.97E-03 2.27E-03 6.51E-03
10-yr 1.07 1.91E-03 1.60E-03 1.55E-03 4.69E-03
20-yr 1.17 2.44E-03 2.12E-03 1.90E-03 5.92E-03
a Estimates are excess relative risk per lg/m3-yr.
b 95% LCL = b  (1.645  SE).
c 95% UCL = b + (1.645  SE).
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long-term (i.e., lifetime) exposure (e.g., 60% of the person-years
at risk were from workers employed less than 6 months). Conse-
quently, risk results for workers employed at least 1 year will be
of primary interest and comparable to results based on the Paines-
ville, OH cohort (Crump et al., 2003) and the supporting 4-plant,
low-dose cohort (Applied Epidemiology, 2002), both of which uti-
lized at least 1 year of employment as a criterion for the inclusion
of workers in the cohort. For completeness, however, results for the
Baltimore, MD cohort are also presented for all workers regardless
of employment duration and those employed at least one-half
year.
Cox modeling is superior than Poisson regression modeling in
that Cox modeling uses individual exposure estimates for each
worker (as opposed to the average or midpoint for each exposure
group) as well as the actual age of the worker (as opposed to age
interval groupings), and does not make any assumptions about
the functional form of the background hazard rate. This method
avoids dependence on the partitioning of cumulative exposure
and optimally controls for the effect of age on lung cancer. (The
Poisson model was used for the Painesville cohort discussed in
the previous section because the Cox model requires more infor-
mation than the summary data that were available for the Paines-
ville study.) The effect of smoking and the effect of race on the
model ﬁt to the lung cancer mortality were assessed separately
and concurrently. The data were split into three strata (non-smo-
ker, smoker, unknown smoking) to adjust the model parameters
for the effect of smoking and into two strata (white and non-white)
to adjust the model parameters for the effect of race. The impact of
these covariate effects were analyzed for the full cohort and the
two subcohorts of workers employed at least one-half year and
at least 1 year at the Baltimore plant (see Table 4 below).
More speciﬁcally, the log-linear form of the Cox proportional
hazards model was used to ﬁt the epidemiological data of the Bal-
timore cohort and to adjust for the effects of covariates. That Cox
model can be speciﬁed as follows:
lnðRRijÞ ¼ si þ rj þ b CumExp
where si is the effect of smoking for the i-th smoking group relative
to the reference smoking group, rj is the effect of race relative to the
reference race group, and b is the change in the ln(RRij) per unit
change in the cumulative exposure (CumExp). The Cox-proportional
hazards model was ﬁt to the Baltimore epidemiological data usingTable 4
Statistics for the Baltimore cohort and two subsets with different minimum lengths of em
Workers included Number of workers Workers without
Number Sm
All 2357 2235 171
Employment durationP 0.5 years 1086 1017 79
Employment durationP 1.0 years 823 767 60Version 9.2 of the SAS System for Windows SAS/STAT software
(2002).
The impact of adding each of the covariate effects on the model
ﬁt to the data was evaluated using the improvement (i.e., reduc-
tion) of the deviance (deviance = 2  log likelihood) when the
covariate was included in the model versus the deviance when
the covariate was not included in the model. The decrease in the
deviance was compared to a chi-square distribution to evaluate
the statistical signiﬁcance of the improvement of the model ﬁt to
the data. Table 5 shows the deviances for the models ﬁt to the full
cohort and two subcohorts. The deviance of the model adjusted for
smoking is statistically signiﬁcantly (p-value < 0.01) less than the
deviance of the model not adjusted for any covariate for the full co-
hort and for the two subcohorts analyzed. In contrast, although the
adjustment for race results in a statistically signiﬁcant (p-va-
lue < 0.05) reduction in the deviance for the subcohort of workers
employed at least 1 year, it does not result in a statistically signif-
icant reduction in the deviance for the full cohort and the subco-
hort of workers employed at least half a year. The deviance of
the model adjusted for smoking and race is statistically signiﬁ-
cantly (p-value < 0.01) less than the deviance of the model not ad-
justed for any covariate for the full cohort and the two subcohorts
analyzed. However, the statistically signiﬁcant decreases of the
deviance when both covariates are included in the model are dri-
ven by the effect of smoking and only marginally due to the effect
of race.
Based on these results, the model without covariates and the
model that included smoking as a covariate (which drove statisti-
cal signiﬁcant decreases of the deviance) were analyzed further to
determine the optimal exposure lag. That is, the effect of cumula-
tive exposure lag on the model ﬁt to the epidemiological data was
analyzed. The lag adjusts the cumulative exposures to account for
the potential latency and induction periods of lung cancer mortal-
ity in the cohort. The optimal lag was estimated for lung cancer
mortality in the full cohort and in the two subcohorts.
Table 6 lists the deviances (2  log likelihood) for each of the
two models (without covariates and with smoking as a covariate),
for each of the three subsets of the data (all workers, workers hired
for at least half a year, and workers hired for at least 1 year), and
for three lag periods (no lag, 5 years, and the lag with the minimum
deviance which is the same as the lag that maximizes the likeli-
hood). Both models ﬁt the lung cancer mortality data better when
the lag is set equal to 5 years than when no lag is used. Both mod-
els also ﬁnd that the lag that maximizes the likelihood of the modelployment duration.
lung cancer Workers that died with lung cancer
oker (%) White (%) Number Smoker (%) White (%)
6 (76.78) 1134 (50.74) 122 118 (96.72) 71 (58.20)
2 (77.88) 531 (52.21) 69 68 (98.55) 38 (55.07)
1 (73.03) 413 (50.18) 56 55 (98.21) 29 (51.79)
Table 5
Deviance for three subsets of the Baltimore cohort based on the Cox proportional hazards model with unlagged exposure.
Covariates in addition to cumulative CrVI exposure All workers Only workersP 0.5 years of employment Only workersP 1.0 years of employment
None 1629.256a 798.815 623.071
Smokingb 1609.261** 784.358** 611.721**
Racec 1627.951 796.603 617.539*
Smoking & race 1608.128** 782.61** 606.531**
* Deviance is statistically signiﬁcantly < deviance of the model without covariates at the 5% signiﬁcance level.
** Deviance is statistically signiﬁcantly < deviance of the model without covariates at the 1% signiﬁcance level.
a Deviance = 2  log-likelihood.
b Smoking is a categorical covariate with three categories: ‘‘non smoking’’, ‘‘smoking’’, and ‘‘unknown smoking’’.
c Race is a categorical covariate with two categories: ‘‘white’’ and ‘‘non-white’’.
Table 6
Deviance for three subsets of the Baltimore cohort based on the Cox proportional hazards model with 0, 5 year, and optimal exposure lag.
Exposure lag All workers Only workersP 0.5 years of employment Only workersP 1.0 years of employment
Covariates: none
None 1629.256a 798.815 623.071
5-yr 1628.328 797.858 621.924
Optimal lag (MLE of the lag) 1628.145 lag = 6.3 years 797.653 lag = 6.7 years 621.620 lag = 7.4 years
Covariates: smokingb
None 1609.261 784.358 611.721
5-yr 1608.407 783.502 610.705
Optimal lag (MLE of the lag) 1608.259 lag = 6.3 years 783.33 lag = 6.7 years 610.456 lag = 7.4 years
a Deviance = 2  log-likelihood.
b Smoking is a categorical covariate with three categories: ‘‘non smoking’’, ‘‘smoking’’, and ‘‘unknown smoking’’.
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for the different subcohorts. The deviances for the models with
exposure lag are less than the deviances for the models without
exposure lag (although the improvements in the ﬁt are not statis-
tically signiﬁcant at the 5% signiﬁcance level).
Table 7 presents b estimates for the Baltimore, MD cohort with
smoking as a covariate (statistical signiﬁcant decreases in model
deviance are driven by the effect of smoking) and the optimal lag
period in units of increase in relative risk per lg CrVI/m3-yr, with
b estimates for no lag and 5 year exposure lag provided for com-
parison. As can be seen from Tables 3 and 7, use of the better
Cox model for the Gibb et al. (2000) data on the Baltimore, MD co-
hort provides b values fairly consistent with those of Crump et al.
(2003) for the Painesville, OH cohort (e.g., 5 year lag bMLE range of
8.19E-04–1.00E-03 compared to the b MLE from Crump et al. of
6.34E-04). Since the statistically signiﬁcant decrease of the devi-
ance in the model is driven by the effect of smoking and the opti-
mum exposure lag optimizes model ﬁt, this will be the analysis of
primary interest for workers employed at least 1 year (the pre-
ferred worker subset upon which to base risk estimates due toTable 7
Cox model b values and standard error (SE) based on Gibb et al. (2000) individual data for t
lags.
Worker group Exposure lag SE
All workers 6.3-yr (optimum) 2.
5-yr 2.
None 2.
Only workersP 0.5 years of employment 6.7-yr (optimum) 2.
5-yr 2.
None 2.
Only workersP 1.0 years of employment 7.4-yr (optimum) 2.
5-yr 2.
None 2.
a Estimates are increase in relative risk per lg/m3-yr.
b 95% LCL = b  (1.645  SE).
c 95% UCL = b + (1.645  SE).long-term exposure). The b MLE for the preferred analysis (i.e.,
workers employed P1 year, smoking as a covariate, optimum
exposure lag) is bolded in the table below.3.4. Dosimetric adjustments
Occupational concentrations (concentrationOC) were converted
to environmental concentrations for the general population (con-
centrationHEC) using the following equation (TCEQ, 2012):
ConcentrationHEC ¼ concentrationOC  ðVEho=VEhÞ
 ðdays per weekoc=days per weekresÞ
where: VEho = occupational ventilation rate for an 8 h day (10 m3/
day); VEh = non-occupational ventilation rate for a 24 h day
(20 m3/day); days per weekoc = occupational weekly exposure fre-
quency (default of 5 days per week); days per weekres = residential
weekly exposure frequency (7 days per week).he Baltimore cohort with smoking as a covariate and optimum, 5, and 0 year exposure
b (95% LCL)a,b b (MLE)a b (95% UCL)a,c
33E-04 6.37E-04 1.02E-03 1.40E-03
31E-04 6.20E-04 1.00E-03 1.38E-03
28E-04 5.72E-04 9.47E-04 1.32E-03
70E-04 3.99E-04 8.43E-04 1.29E-03
67E-04 3.83E-04 8.22E-04 1.26E-03
66E-04 3.19E-04 7.57E-04 1.19E-03
88E-04 3.78E-04 8.52E-04 1.33E-03
84E-04 3.52E-04 8.19E-04 1.29E-03
83E-04 2.72E-04 7.38E-04 1.20E-03
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3.5.1. Study-speciﬁc URFs
URFs express cancer potency in units of excess risk per air con-
centration (e.g., excess risk per lg/m3) assuming continuous life-
time exposure. They are calculated using linear low-dose
extrapolation when the carcinogenic MOA is mutagenic, unknown,
or sufﬁcient information to justify an alternative extrapolation ap-
proach is not available (TCEQ, 2012). Although there is not a con-
sensus on the speciﬁc MOA for CrVI, signiﬁcant information
relevant to the carcinogenic MOA for CrVI is known and justiﬁes
at least the consideration of a nonlinear-threshold assessment in
addition to the default linear low-dose extrapolation approach em-
ployed in this paper. The implementation of an exploratory nonlin-
ear-threshold approach was published recently in Haney et al.
(2012). However, at this time the uncertainties associated with a
nonlinear-threshold inhalation carcinogenic assessment for CrVI
appear to preclude a robust scientiﬁc justiﬁcation for deviation
from the default linear low-dose extrapolation approach. Thus,
the focus of the current study is use of the default linear low-dose
extrapolation approach to derive URF estimates.
The BEIR IV methodology (NRC, 1988) was used to estimate
CrVI URFs based on the b values calculated from human dose–re-
sponse data (as discussed in Section 3.3). The BEIR IV life-table
analyses were used to calculate separate URFs for the key studies
of Crump et al. (2003) and Gibb et al. (2000) (as well as the sup-
porting study of Applied Epidemiology (2002)) prior to combining
the key study URF estimates through a weighting procedure for the
ﬁnal CrVI URF.
Table 8 shows URFs estimated for the key study of Crump et al.
(2003), as well as the supporting study of Applied Epidemiology
(2002). Additionally, Table 8 provides extrapolated air concentra-
tions corresponding to a de minimis excess cancer risk of 1 in
100,000 based on b (MLE), b (95% LCLs), and b (95% UCLs) from Ta-
ble 3, which were calculated using maximum likelihood estimation
with Poisson regression. For the Cox proportional hazardsmodeling
of the Gibb et al. (2000) data for the Baltimore, MD cohort, Table 9
provides estimates of URFs aswell as air concentrations at a demini-
mis 1 in 100,000 excess cancer risk based on b (MLE), b (95% LCLs),
and b (95%UCLs) fromTable 7. Air concentrations are based on extra
risk (as opposed to added risk) and a lifetime exposure of 70 years,
the default used by TCEQ for exposure analysis (TCEQ, 2012), and
were solved iterativelywith life-table analyses using the BEIR IV ap-
proach (NRC, 1988). The following lung cancer mortality rates and
survival probabilities were used in the primary analyses:
 Texas-speciﬁc lung cancer mortality rates for 2005–2009 and
Texas-speciﬁc survival rates for 2010 are the latest available
(TDSHS, 2010).Table 8
URFs and air concentrations corresponding to 1 in 100,000 excess lung cancer mortality.
Study Exposure
lag
Background
rates
Crump et al. (2003) Painesville, OH 5-yr TX
Applied Epidemiology (2002) Leverkusen and Uerdingen,
Germany, Corpus Christi, TX and Castle Hayne, NC
None TX
10-yr TX
20-yr TX
NA = as the 95% LCL b value was negative, suggesting zero excess risk, calculation of an
a Calculation of air concentrations at 1 in 100,000 excess risk used the unrounded URAlthough Texas background lung cancer mortality rates and
survival probabilities are preferred by the TCEQ and were used
for the results shown in Tables 8 and 9 below, similar results were
obtained using US rates and are available in TCEQ (2013).
3.5.2. Selection of preferred lung cancer URFs
Based on the two key epidemiological studies (Crump et al.,
2003; Gibb et al., 2000), two lung cancer URFs are selected in this
section for combining into a ﬁnal weighted URF. As indicated pre-
viously, Crump et al. (2003) provide one of the best summary SMR
datasets for dose–response assessment due to a relatively high
number of exposure groups (10) evaluated for excess lung cancer
risk (14,443 person-years). Because exposure was not lagged and
fewer cumulative exposure groups are provided by Luippold
et al. (2003) for dose–response modeling, Crump et al. are consid-
ered to provide the best dose–response dataset for the Painesville,
OH cohort. Thus, the preferred URF for the Painesville cohort
(shaded in Table 8, associated b shaded in Table 3) will be based
on the 5 year exposure lagged data from Crump et al. (2003).
For Gibb et al. (2000), URFs based on Cox proportional hazards
modeling for workers employed at least 1 year are preferred given:
(1) the superiority of the Cox model over Poisson regression, (2)
TCEQ’s reservations about inclusion of very short-term workers
in Gibb et al. (2000) to assess the excess risk associated with
long-term (e.g., lifetime) CrVI exposure, and (3) comparability con-
siderations (i.e., Crump et al. (2003) and the supporting Applied
Epidemiology (2002) study utilized 1 year of employment as a
worker inclusion criterion). It is noted, however, that the URFs
are fairly similar for the employment durations evaluated (e.g.,
the all worker 5 year lag MLE URF is only 22% higher than that
for workers employed at least a year). Furthermore, use of the opti-
mal exposure lag of 7.4 years is preferred as this lag maximizes the
likelihood of the model ﬁt to the data (although use of 5 year lag
provides results within 4% and would result in an identical ﬁnal
weighted URF). The 7.4 year exposure lag is close to the 5 year
lag results being used from Crump et al. (2003). Thus, the preferred
URF for the Baltimore, MD cohort (shaded in Table 9, associated b
shaded in Table 7) will be based on Cox modeling results for work-
ers employed at least 1 year, 7.4 year exposure lagged data, and
smoking as a covariate (see Section 3.3.2).
Regarding the Applied Epidemiology (2002) supporting study,
use of dose–response data from workers exposed to low levels of
CrVI is considered advantageous for assessing low-dose risk as
the magnitude of extrapolation below the range of data and the
uncertainty associated with low-dose extrapolation is reduced.
Thus, although the short follow-up time and low deceased percent
for this cohort are important limitations, results from this support-
ing study are nevertheless considered to have value for comparison
to the URFs based on the two key epidemiological studies. ThreeURF (95% LCL) a URF (MLE) a URF (95% UCL) a
Air concentration @ 1 in
100,000 excess risk
Air concentration @ 1 in
100,000 excess risk
Air concentration @ 1 in
100,000 excess risk
3.21E-04 per lg/m3 1.94E-03 per lg/m3 3.55E-03 per lg/m3
3.11E-02 lg/m3 5.16E-03 lg/m3 2.82E-03 lg/m3
NA 7.55E-03 per lg/m3 2.16E-02 per lg/m3
1.32E-03 lg/m3 4.62E-04 lg/m3
NA 4.33E-03 per lg/m3 1.31E-02 per lg/m3
2.31E-03 lg/m3 7.63E-04 lg/m3
NA 4.30E-03 per lg/m3 1.34E-02 per lg/m3
2.32E-03 lg/m32.05E-03 7.46E-04 lg/m3
air concentration at 1 in 100,000 excess risk was not possible.
F.
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based on different exposure lag periods (0, 10, and 20 year lagged
exposure). An exposure lag of 20 years appears too long consider-
ing that the mean time since ﬁrst exposure for lung cancer mortal-
ity in the high cumulative exposure group which experienced
excess risk in the SMR analysis was around 23 years (Fig. 24 of Ap-
plied Epidemiology (2002)) as this would assume that on average,
only the ﬁrst 3 years of CrVI exposure were potentially causative
for the excess lung cancer mortality observed in this group. Along
this line of reasoning, exposure lags of 0 and 10 years would seem
to provide a more reasonable basis for a supporting URF. However,
the 10 year lagged exposure data seem to provide a SMR exposure–
response closer to linear than the 0 year lag data (Table 2) and pro-
duce a smaller b value variance (3.65E-06) than no lag (6.66E-06)
(Table 3). Additionally, a 10 year lag is more similar to the expo-
sure lags of 5 and 7.4 years, respectively, being used for the Crump
et al. (2003) and Gibb et al. (2000) key studies. Based on these con-
siderations, the preferred supporting URF for the 4-plant, low-dose
worker cohorts (lightly shaded in Table 8, associated b lightly
shaded in Table 3) will be based on the 10 year exposure lagged
data from Applied Epidemiology (2002).
Lastly, as can be seen from Fig. 2, lung cancer mortality is rea-
sonably predictive of lung cancer incidence (i.e., 5 year survival is
only about 16% (American Cancer Society, 2005)). Therefore, if inci-
dence data were available, the lung cancer potency estimates
would be expected to be very similar to those derived based on
lung cancer mortality.
In such instances, the TCEQ selects the URF (MLE) as the best
estimate of cancer potency (e.g., TCEQ (2011)). Additionally,
although values based on US rates are very similar (see TCEQ
(2013)), the TCEQ uses Texas age-speciﬁc lung cancer mortality
rates and survival probabilities to derive URFs.
Therefore, the URFs selected based on the key epidemiological
studies of Crump et al. (2003) and Gibb et al. (2000) are 1.94E-03
and 2.56E-03 per lg CrVI/m3, respectively (Tables 8 and 9). These
URFs are very similar, a factor of only 1.3 apart. They are sup-
ported by a URF of 4.33E-03 per lg CrVI/m3 based on data from
Applied Epidemiology (2002). All three URFs are similar, within
a factor of 2.2, although based on different cohorts and different
lag periods in the cumulative exposure dose metrics. The URFs
from the two key studies will be weighted to calculate a ﬁnal
URF.Table 9
Cox model URFs and air concentrations corresponding to 1 in 100,000 excess lung cancer m
covariate and optimum, 5, and 0 year exposure lags.
Worker group Exposure lag Background
rates
URF (95% LCL)a
Air concentration @ 1
100,000 excess risk
All workers 6.3-yr
(optimum)
TX 1.96E-03 per lg/m3
5.11E-03 lg/m3
5-yr TX 1.95E-03 per lg/m3
5.14E-03 lg/m3
None TX 1.95E-03 per lg/m3
5.12E-03 lg/m3
Only workersP 0.5 years of
employment
6.7-yr
(optimum)
TX 1.22E-03 per lg/m3
8.22E-03 lg/m3
5-yr TX 1.20E-03 per lg/m3
8.31E-03 lg/m3
None TX 1.09E-03 per lg/m3
9.18E-03 lg/m3
Only workersP 1.0 years of
employment
7.4-
yr(optimum)
TX 1.14E-03 per lg/m3
8.79E-03 lg/m3
5-yr TX 1.11E-03 per lg/m3
9.04E-03 lg/m3
None TX 9.28E-04 per lg/m3
1.08E-02 lg/m3
a Calculation of air concentrations at 1 in 100,000 excess risk used the unrounded UR3.6. Weighting preferred URFs for a ﬁnal URF
The ﬁnal URF is derived here using a meta-analysis approach
that combines the two preferred URFs based on the individual
key epidemiological studies. Though meta-analyses usually
combine results of primary research, herein the meta-analysis
combines URFs estimated from published data of primary epidemi-
ological research studies and from individual epidemiological data.
The purpose of this meta-analysis is to integrate the ﬁndings based
on the preferred individual studies into a ﬁnal URF that objectively
incorporates the signiﬁcance of the results (measured by the preci-
sion or variance of the model ﬁt to the data). More speciﬁcally, as
discussed below and in TCEQ (2012), the two key URFs are
weighted based on inverse variance (1/SE2), a standard statistical
procedure used in meta-analyses, to combine them and derive a
ﬁnal URF.
The two preferred URFs based on Crump et al. (2003) and Gibb
et al. (2000) are 1.94E-03 and 2.56E-03 per lg CrVI/m3, respec-
tively. These URFs are similar and are considered appropriate esti-
mates of the carcinogenic potency of CrVI based on their respective
studies. However, in order to incorporate the available information
from both key epidemiological studies, these two URFs are com-
bined to derive a ﬁnal URF using a weighting factor that reﬂects
the relative statistical conﬁdence in the URFs. Variance in the b
values used to derive the preferred URFs reﬂects uncertainty in
the b estimates and is used as a weighting factor. Since there is
generally more conﬁdence in b values with smaller variance, the
reciprocal of the variance is used so that the resulting weighting
factor is larger for the b value with the smallest variance (uncer-
tainty). The URF based on a b with smaller variance receives great-
er weight as conﬁdence is increased because a relatively lesser
variance is an indication of a higher precision of the estimated
parameter. The overall weight for a URF is the percentage of the
sum of URF weighting factors that is represented by the reciprocal
of the variance of the estimated b for that URF (i.e., (individual URF
weighting factor/sum of weighting factors for URFs being
weighted)  100 = overall weight% for a given URF). As shown in
Table 10 below, the variances associated with the b (MLE) values
for the two studies are similar (less than 12% apart), resulting in
similar weighting factors.
The ﬁnal URF is equal to the weighted average (using weight
percents expressed in decimal form) of the two individual URFs:ortality based on Gibb et al. (2000) data for the Baltimore cohort with smoking as a
URF (MLE)a URF (95% UCL)a
in Air concentration @ 1 in
100,000 excess risk
Air concentration @ 1 in
100,000 excess risk
3.13E-03 per lg/m3 4.30E-03 per lg/m3
3.19E-03 lg/m3 2.33E-03 lg/m3
3.14E-03 per lg/m3 4.33E-03 per lg/m3
3.18E-03 lg/m3 2.31E-03 lg/m3
3.23E-03 per lg/m3 4.51E-03 per lg/m3
3.09E-03 lg/m3 2.22E-03 lg/m3
2.57E-03 per lg/m3 3.93E-03 per lg/m3
3.89E-03 lg/m3 2.54E-03 lg/m3
2.58E-03 per lg/m3 3.96E-03 per lg/m3
3.87E-03 lg/m3 2.53E-03 lg/m3
2.58E-03 per lg/m3 4.06E-03 per lg/m3
3.87E-03 lg/m3 2.46E-03 lg/m3
2.56E-03 per lg/m3 4.00E-03 per lg/m3
3.90E-03 lg/m3 2.50E-03 lg/m3
2.57E-03 per lg/m3 4.05E-03 per lg/m3
3.89E-03 lg/m3 2.47E-03 lg/m3
2.52E-03 per lg/m3 4.10E-03 per lg/m3
3.97E-03 lg/m3 2.44E-03 lg/m3
F.
Table 10
Weighting of preferred URFs from Crump et al. (2003) and Gibb et al. (2000).
Study Preferred URF (per lg CrVI/m3) Standard error (SE) of bc Weighting factor (1/SE2) Overall weight of URF (%)d
Crump et al. (2003) 1.94E-03a 3.22E-04 9.64E + 06 44.4
Gibb et al. (2000) 2.56E-03b 2.88E-04 1.21E + 07 55.6
a See Table 8.
b See Table 9.
c See Tables 3 and 7 for the values of the SE of b.
d Overall weight of URF (%) = (weighting factor/sum of weighting factors)  100.
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Crump et al. (2003) + Gibb et al. (2000)
URF  overall weight for Gibb et al. (2000)
= 1.94E-03  0.444 + 2.56E-03  0.556
= 2.28E-03 per lg CrVI/m3
Thus, the ﬁnal URF when rounded to two signiﬁcant ﬁgures is
2.3E-03 per lg CrVI/m3. Based on the ﬁnal URF, the air concentra-
tion corresponding to a de minimis excess lung cancer mortality
risk of 1 in 100,000 (rounded to two signiﬁcant ﬁgures), for exam-
ple, is 0.0043 lg CrVI/m3 (i.e., 0.00001/2.3E-03 per lg CrVI/m3).
Using US lung cancer mortality and survival rates would result in
a very similar URF (2.4E-03 per lg CrVI/m3) and air concentration
at a 1 in 100,000 excess risk (0.0042 lg CrVI/m3) (see TCEQ
(2013)).
3.7. Uncertainty analysis
There are several uncertainties associated with the calculation
of URFs in general and the URFs calculated herein. The primary
uncertainties are those associated with dose–response modeling,
estimating risks for the general population from occupational
worker data, potential exposure estimation error, and co-expo-
sures to other compounds. In regard to occupational worker data,
use of a cumulative dose metric from high, less-than-lifetime occu-
pational exposure for dose–response assessment results in some
uncertainty when estimating risk for the general public based on
much lower, lifetime average exposure levels. For example, if dose
rate plays an important role in overwhelming protective mecha-
nisms (e.g., lung CrVI extracellular reductive capacity) and produc-
ing excess lung cancer risk, a URF based on high, shorter duration
occupational exposure may be conservative for estimating risk at
low, lifetime environmental exposure levels. Regarding dose–re-
sponse modeling, URFs calculated with slope b parameter esti-
mates for the 95% LCL, MLE, and 95% UCL were reported for each
analysis in order to provide information on uncertainty in the risk
estimates based on the different cohorts. One of the primary areas
of interest in terms of uncertainty regards the similarities and/or
differences in study URFs:
For the Crump et al. (2003) study:
 URF estimates range from 3.21E-04 per lg/m3 (95% LCL) to
3.55E-03 per lg/m3 (95% UCL), a ratio of around 11;
 The preferred URF of 1.94E-03 per lg/m3 (MLE) is within a fac-
tor of 2 of the 95% UCL URF.
For the Gibb et al. (2000) study:
 URF estimates for workers employed at least a year with opti-
mum lag and smoking as a covariate (the preferred analysis)
range from 1.14E-03 per lg/m3 (95% LCL) to 4.00E-03 per lg/
m3 (95% UCL), a ratio of around 3.5;
 The preferred URF of 2.56E-03 per lg/m3 (MLE) is within a
factor of 1.6 of the 95% UCL URF; URF estimates for all workers (including those employed less
than a year) with optimum lag and smoking as a covariate ran-
ged from 1.96E-03 per lg/m3 (95% LCL) to 4.30E-03 per lg/m3
(95% UCL), a ratio of around 2.2;
 The MLE URF of 3.13E-03 per lg/m3 for all workers is a factor of
1.2 apart from the preferred MLE URF for workers employed at
least 1 year.
For the preferred analyses of the two key studies, the ratio of
the URF (95% UCL) to the preferred URF (MLE) ranged from 1.56
for Gibb et al. (2000) to 1.83 for Crump et al. (2003), which indi-
cates the precision of the estimates. Additionally, across the studies
the ratio of the highest preferred URF (MLE) of 2.56E-03 per lg/m3
(from Gibb et al. (2000)) to the lowest preferred URF (MLE) of
1.94E-03 per lg/m3 (from Crump et al. (2003)) was 1.3, which indi-
cates good agreement between dose–response modeling from the
different cohort studies. Refer to TCEQ (2013) for a more detailed
uncertainty analysis.4. Discussion and Conclusions
The URF was developed based on new dose–response analyses
of extra lung cancer risk in two key epidemiological studies of
chromate production workers (Crump et al., 2003; Gibb et al.,
2000), with support provided by a dose–response assessment of
a worker cohort from four low-dose chromate plants (Applied
Epidemiology, 2002). For the key Crump et al. (2003) study and
the supporting study, grouped observed and expected number
of lung cancer mortalities along with the cumulative exposures
to CrVI were used to ascertain the MLE and asymptotic variance
of the slope (b) for the linear multiplicative relative risk model
using Poisson regression modeling. For the key Gibb et al.
(2000) study, Cox proportional hazards modeling was conducted
with optimal exposure lag and adjusting for the effect of covari-
ates (e.g., smoking) to estimate b values as more detailed, individ-
ual data were available. Life-table analyses were used to develop
URFs for each of the two key studies, which were then combined
using weighting factors pertinent to conﬁdence to derive the ﬁnal
URF for CrVI of 2.3E-03 per lg CrVI/m3. The corresponding 104,
105, and 106 excess risk air concentrations assuming continu-
ous lifetime exposure are 0.042, 0.0042, and 0.00042 lg CrVI/
m3, respectively.
In conclusion, this new URF (2.3E-03 per lg CrVI/m3) is
based on current dose–response analyses and may be utilized
in the evaluation of long-term (e.g., lifetime) air concentrations
for all CrVI compounds and is considered sufﬁciently health-
protective for use in protecting the general public against the
potential carcinogenic effects of chronic exposure to CrVI in
ambient air.Conﬂict of interest
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